Treating COVID-19 with Immune Modulator Drugs

Topline results of a recent clinical trial showed that infliximab or abatacept “substantially improve[ed] clinical status and reduc[ed] deaths” in adult patients hospitalized with severe COVID-19. These drugs are often used to treat certain autoimmune diseases, including rheumatoid arthritis, psoriatic arthritis, Crohn’s disease, and ankylosing spondylitis.

Read More »

FDA Updates Recommendation Around AstraZeneca’s Evusheld

The FDA has revised its emergency use authorization for AstraZeneca’s Evusheld, a monoclonal antibody treatment for COVID-19. Due to emerging data, it has been observed that the original 150mg dose of each monoclonal antibody may be less likely to prevent infection than originally indicated. Thus, the FDA has authorized a double dose of each antibody for immunocompromised patients.

Read More »